What Is Corticotropin and Why Does Legal Status Matter?
Corticotropin, also known as adrenocorticotropic hormone (ACTH), is a peptide hormone that stimulates the adrenal glands to produce cortisol. Clinical trials spanning over 185 studies worldwide have documented its use in diagnosing and treating adrenal insufficiency, infantile spasms, and other endocrine conditions.
Legal status matters because it determines:
- Whether a doctor can prescribe it
- How it's manufactured and quality-controlled
- What information is available to patients
- Whether it's covered by the NHS or requires private payment
Corticotropin's Regulatory Status: The Global Picture
Corticotropin has a fragmented approval landscape:
USA (FDA-approved): The FDA approved corticotropin formulations including repository corticotropin injection (RCI) in 2010. This approval was based on clinical evidence from trials in infantile spasms, giving practitioners confidence in safety and efficacy.
EU/EMA (Not authorised): The European Medicines Agency has not granted a centralised marketing authorisation for corticotropin. This is a critical point: the EMA's refusal to authorise doesn't mean the substance is illegal, but it does mean pharmaceutical companies cannot legally market corticotropin-based medicines across the EU under a single EMA approval.
UK (Post-Brexit nuance): Since Brexit, the UK is no longer bound by EMA decisions, yet the Medicines and Healthcare products Regulatory Agency (MHRA) has largely retained EMA-aligned standards. The MHRA's guidance on human medicines classification means corticotropin products must either hold a UK-specific marketing authorisation or operate under exemptions for unlicensed medicines.
Is Corticotropin Prescription-Legal in the UK?
Yes—under licensed pathways. The product Synacthen (tetracosactide, a synthetic corticotropin analogue) has been available on UK prescription for decades. Synacthen is used diagnostically to test adrenal function and therapeutically in conditions like infantile spasms and autoimmune disorders.
UK doctors can and do prescribe corticotropin via:
- Licensed medicines: Branded products like Synacthen that hold UK marketing authorisations
- Specials (unlicensed medicines): Pharmacy compounding under 503B Outsourcing Facility equivalents or UK specials licences, for patients who cannot use licensed alternatives
- Named-patient basis: GPs and consultants can prescribe unlicensed corticotropin formulations when a licensed alternative is unsuitable, following MHRA guidance
Why Isn't Corticotropin EMA-Authorised?
The EMA's lack of authorisation reflects:
- Older approval timelines: Corticotropin predates modern EMA centralised procedures. Earlier approvals under national procedures were grandfathered but not converted to EMA authorisation.
- Commercial considerations: Corticotropin is an older hormone therapy; pharmaceutical investment in new EMA applications for established agents is often limited.
- Manufacturing complexity: Natural and synthetic corticotropin peptides require careful characterisation, and meeting current EMA chemistry/manufacturing standards can be costly.
This regulatory gap does not make corticotropin illegal in the UK. It simply means prescribing and supply operate under different legal frameworks than, for example, abaloparatide, which has sought modern EMA authorisation for osteoporosis.
UK Prescribing Rules and Practical Availability
On the NHS: Corticotropin (as Synacthen) is available but restricted. NICE guidance and local NHS formularies govern when it can be prescribed. Infantile spasms is a key approved indication; off-label use in other conditions is possible but requires justification.
Private prescription: UK private clinicians can prescribe corticotropin more flexibly, though the substance itself must be sourced from licensed suppliers. Costs are higher than in the US.
Import and supply: Bringing corticotropin into the UK from overseas (e.g., from US suppliers) for personal use is illegal without a UK prescription. UK Customs and MHRA enforcement target unlicensed importation, particularly of uncontrolled peptide hormones.
This is a crucial distinction from some research peptides. Unlike investigational compounds, corticotropin's legal status is not ambiguous—it is a licensed medicine subject to the Medicines Act 1968 and Human Medicines Regulations 2012.
Comparing Corticotropin to Other Peptide Hormones
For context, abarelix, a GnRH antagonist, faced similar regulatory fragmentation: FDA-approved in the US but never EMA-authorised, making UK access rare. ACE-031, a myostatin antagonist, remains investigational globally and is not legally available in the UK outside clinical trials.
Corticotropin occupies middle ground: it's fully licensed and available in the UK, yet more tightly regulated than in the US.
Key Takeaways for UK Residents
- Corticotropin is legal in the UK when prescribed by a registered healthcare practitioner for an appropriate indication.
- Synacthen (synthetic corticotropin) is the main licensed product available on NHS prescription.
- EMA non-authorisation does not equal illegality—the UK operates its own regulatory framework post-Brexit.
- Importing corticotropin without a UK prescription is illegal and subject to MHRA enforcement.
- Access is narrower than in the US due to NHS formulary restrictions and lack of direct US-style availability.
If you need corticotropin for a medical condition, consult your GP or an endocrinologist. They can advise on licensed options and whether your condition qualifies under NHS or private pathways.
Regulatory Nuance: Research vs. Clinical Use
It's worth noting that corticotropin used in research settings (e.g., as a diagnostic marker in clinical studies) is also subject to UK medicines law. Unlike some investigational peptides that operate in grey zones, corticotropin's long history and clinical utility mean it is treated as a regulated pharmaceutical, not a research chemical.